Workflow Designed to Maximize Diversity and Speed in the Discovery of Fully Human Therapeutic Antibodies
WORKFLOW
AT A GLANCE
Workflows
Recovery
Functional
Characterization
Purification
Antibodies
Developability
Assessment
AlivaMab Discovery Services is the only organization that combines the most broadly adopted human therapeutic antibody discovery technology with the most robust discovery processes. Our end-to-end discovery workflow (including sequencing) produces fully human, functionally characterized, therapeutic antibodies in as little as 8 weeks.
Diversity:
- Enrichment for all types of IgG+ B cells, not just plasma cells, ensures better recovery and subsequent interrogation of the molecularly-diverse antigen-specific IgG repertoire
- High-throughput screening capabilities, over 105 hybridomas, ensure maximum coverage to identify antibodies with optimal properties and diverse epitopes, including exceptionally rare antibodies
Speed:
- Proprietary suite of immunization strategies ensures a superlative immune response within as little as two weeks, not months
- A “function first” approach can allow detailed characterization of antibodies early in the discovery process, 11 days after completion of immunization
- Time consuming steps of humanization and in vitro optimization for affinity and developability are eliminated
Technology:
- With a majority of top-15 pharmaceutical companies using AlivaMab Mouse, it is the most broadly adopted human therapeutic antibody discovery technology, including in vitro display and other transgenic platforms
- Designed for successful antibody drug discovery and development
- Uniquely optimized constant domains and human V repertoire
Our Optimized Processes Increase Leads While Reducing Timelines
Days per step may vary based on the details of your project.
CUSTOM DESIGNED WORKFLOWS
DEVELOPED IN COLLABORATION
Each project has a custom workflow to meet the target product profile and leverages proprietary immunization strategies.
IMMUNIZATION STRATEGIES
THAT MAXIMIZE IMMUNE RESPONSE
Day 0
Immunization strategies and proprietary adjuvants (AMMPD-2, -4, DNA, VAC) combined with tolerance breaking approaches insure a robust immune response.
ANTIBODY RECOVERY
YIELDS 105 HYBRIDOMAS
Day 14
- Enrichment for all types of IgG+ B cells, not just plasma cells — more than enough hybridomas to enable the identification of diverse and rare antibodies.
SCREENING AND FUNCTIONAL CHARACTERIZATION
HUNDREDS TO THOUSANDS OF HITS
Day 23
Early functional testing and high throughput capacity is used to identify antibodies with ideal properties.
SEQUENCING AND PURIFICATION
99%+ RECOVERY
Day 40
Our process includes over 99% HC/LC V region recovery, V region sequence & analyses and SEC-HPLC characterization of antibodies.
LEAD ANTIBODIES
DIVERSE HUMAN ANTIBODY LEADS AND BACKUPS
Day 54
We’ll provide you with panels of diverse antibodies, their sequences (DNA and protein) and a data report.
EXPRESSION AND DEVELOPABILITY ASSESSMENT
REDUCES ATTRITION
Scalable, fully human, recombinant expression in CHO and supporting developability assessment.
How Our Team Works with You
Entrusting your antibody discovery project to an external partner is a critical decision. Every discovery project is unique. We will work with you to design a discovery campaign tailored to the needs of your project.
We understand what is at stake because we have led therapeutic discovery and development projects ourselves. Our engagement with you will be guided by tenets of good science, urgency, accountability and responsibility, focused on discovery of the best therapeutic lead candidate antibodies. We are committed to the success of your project.